Long-term follow-up after a Kite gene-cell infusion
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study checks on people long after they received a gene-modified cell infusion in a Kite-sponsored study. It helps researchers understand how treatments work over time and watch for any long-term effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have already received a gene-modified cell infusion in a completed Kite-sponsored parent study
- You have not fully withdrawn your permission to be in the study
- You have finished the post-treatment follow-up part of the parent study (or stopped it if the study allowed it)
- You must understand the study and sign (or have your assent signed) before any study visits or tests
- The research team must feel you can and will attend scheduled follow-up visits and follow study instructions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is a long-term follow-up for people who previously received a gene therapy treatment called zamtocabtagene autoleucel in a Miltenyi Biomedicine-sponsored clinical study. It helps researchers monitor your health over time after the treatment.
This trial studies two investigational cell therapies (KITE-363 or KITE-753) in people whose B-cell lymphoma has returned or did not respond to prior treatment. The goal is to see how safe the treatments are and how well they can shrink the lymphoma.
This is a long-term follow-up study for people who have already received gene-modified T-cell therapy. It observes your health over time to see how well the treatment worked and any long-term effects.
This study is a long-term check-in for people who previously received gene-modified T-cell infusions in a related Celgene/Juno/BMS trial. It helps researchers track safety and long-term effects over time.
This study checks long-term health after receiving a gene-modified cell therapy through a St. Jude study. It helps doctors understand the treatment’s lasting effects and safety over time.
This study is a long-term follow-up for people who have already received Inaticabtagene Autoleucel, a type of cell therapy. It checks how patients are doing over time, and does not involve any new treatments.
Hear when a new Solid and Hematological Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.